Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
rated new Buy at Jefferies. $365 price target. Company has more potential catalysts into 2011 and should exceed consensus earnings expectations.
rated new Buy at Canaccord Genuity. $38 price target. Company is a well-positioned industry leader.
upgraded at Goldman from Neutral to Buy. $95 price target. Expect better flows to foreign equities and alternatives.
downgraded at Goldman from Buy to Neutral. Stock was also removed from the Conviction List. Valuation call, based on a $180 price target.
downgraded at Deutsche to Hold. Company faces cost pressures. $55 price target.
downgraded at Barclays to Underweight from Equal Weight as a more challenging competitive environment will create headwinds for Colgate's earnings growth going forward, Barclays said. Price target cut to $68 from $80.
rated new Hold at Canaccord Genuity. Valuation call, based on a $105 price target.
downgraded at BofA/Merrill to Underperform from Neutral given doubts of sustainable momentum in electricity prices due to a low natural gas price and capital allocation uncertainty. Maintain $17.50 price target on healthy FCF yield.
downgraded at Goldman from Buy to Neutral. $35 price target. Channel checks are softening and the company faces difficult comps over the next two months.
rated new Buy at Goldman Sachs. Company is at the epicenter of the ongoing revolution in genomics.
rated new Buy at Canaccord Genuity. $52 price target. Company is a clear market leader and should benefit from secular growth trends.
initiated at Credit Suisse with an Outperform rating and $44 price target. Strong balance sheet and margin improvement realistic.
K-Sea Transportation Partners
downgraded at Barclays to Underweight from Equal Weight. KSP used the proceeds of a KA First Reserve equity investment to reduce indebtedness on its credit facility, Barclays noted. Price target fell to $5 from $10.
initiated at Barclays with an Overweight rating and $46 price target. Attractive valuation, healthy dividend, and rate issues being resolved in 4Q10 could be catalyst.
rated new Buy at Canaccord Genuity. $32 price target. Company has a full product suite and should perform well in the next upgrade cycle.
upgraded at Deutsche from Hold to Buy. $49 price target. Stock is already pricing in regulatory risks.
Research in Motion
rated new Hold at Jefferies. $55 price target. New products need to gain traction, in order for the stock to recover.
downgraded at Credit Suisse to Underperform from Neutral. Falling margins likely to follow weak sales. Price target reduced to $15 from $18.
upgraded at BofA/Merrill to Neutral from Underperform as an improved industry outlook and a solid project pipeline point to upside potential. CFO recently bought 15,000 shares. Maintain $16 price target.
upgraded at Jefferies from Hold to Buy. $45 price target. Company is executing well and could have a strong flu season.
rated new Buy at Goldman Sachs. Core HPLC franchise should see a strong upgrade cycle.
STOCK COMMENTS / EPS CHANGES
estimates, target increased at UBS through 2011. Company is leveraged to higher tablet computer sales. Buy rating and new $10 price target.
target cut at FBR to $45. DOJ lawsuit will likely hang over the stock.
estimates reduced at Morgan Stanley through 2012. Company may have to lower its U.S. merchant discount rate. Overweight rating and $52 price target.
numbers lowered at Jefferies to $47. Estimates also cut, as the macro environment could weigh on growth. Hold rating.
target boosted at Goldman. Shares of BIDU now seen reaching $105. Quality and pace of the company's growth is improving.
price target trimmed at Citi to $25 from $30 as estimates were revised for post deal closing. Maintain Hold rating.
estimates increased at Jefferies through 2011. Volume should continue to recover into the fourth quarter. Buy rating and $340 price target.
price target higher at Barclays. COT price target lifted to $9 from $8. Investors favor strategic merits of Cliffstar deal and margin expansion is possible. Maintain Overweight rating.
target cut at Goldman to $41. Non-regulated business will be hurt by lower power and gas prices. Buy rating.
price target boosted at Barclays to $75 from $65 on positive data regarding Edwards' Sapien transcatheter heart valve. Maintain Overweight rating.
estimates boosted at Jefferies 2011. Futures volumes remain strong. Hold rating and $120 price target.
price target higher at Barclays to $64 from $58 on continued global momentum and the CCE deal. Maintain Overweight rating.
Las Vegas Sands
numbers upped at Sterne Agee through 2012. Company continues to see growth in Singapore and also has a potential opportunity in Japan. Buy rating and new $45 price target.
estimates, target lowered at ThinkEquity. Shares of MU now seen reaching $14. Estimates also cut, given weaker memory demand and pricing. Buy rating.
estimates, target raised at Goldman. Shares of NUVA now seen reaching $36. Prices are holding up better than expected. Neutral rating.
Thomas & Betts
numbers raised at Citigroup. Shares of TNB now seen reaching $43. Estimates also increased, as recent acquisitions should add to earnings. Hold rating.
This article was written by a staff member of TheStreet.